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18F-FLT Positron Emission Tomography/Computed Tomography 
Imaging in Pancreatic Cancer: Determination of Tumor Proliferative 
Activity and Comparison with Glycolytic Activity as Measured by 
18F-FDG Positron Emission Tomography/Computed Tomography 
Imaging
Pankreas Kanserinde 18F-FLT Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi 
Görüntülemesi: Tümör Çoğalma Hızının Belirlenmesi ve 18F-FDG Pozitron Emisyon 
Tomografi/Bilgisayarlı Tomografi ile Ölçülen Glikolitik Aktivite ile Karşılaştırılması 
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Abstract
Objective: This phase-I imaging study examined the imaging characteristic of 3’-deoxy-3’-(18F)-fluorothymidine (18F-FLT) positron 
emission tomography (PET) in patients with pancreatic cancer and comparisons were made with (18F)-fluorodeoxyglucose 
(18F-FDG). The ultimate aim was to develop a molecular imaging tool that could better define the biologic characteristics 
of pancreas cancer, and to identify the patients who could potentially benefit from surgical resection who were deemed 
inoperable by conventional means of staging.
Methods: Six patients with newly diagnosed pancreatic cancer underwent a combined FLT and FDG computed tomography 
(CT) PET/CT imaging protocol. The FLT PET/CT scan was performed within 1 week of FDG PET/CT imaging. Tumor uptake of 
a tracer was determined and compared using various techniques; statistical thresholding (z score=2.5), and fixed standardized 
uptake value (SUV) thresholds of 1.4 and 2.5, and applying a threshold of 40% of maximum SUV (SUVmax) and mean 
SUV (SUVmean). The correlation of functional tumor volumes (FTV) between 18F-FDG and 18F-FLT was assessed using linear 
regression analysis. 
Results: It was found that there is a correlation in FTV due to metabolic and proliferation activity when using a threshold 
of SUV 2.5 for FDG and 1.4 for FLT (r=0.698, p=ns), but a better correlation was obtained when using SUV of 2.5 for both 
tracers (r=0.698, p=ns). The z score thresholding (z=2.5) method showed lower correlation between the FTVs (r=0.698, p=ns) 
of FDG and FLT PET.
Conclusion: Different tumor segmentation techniques yielded varying degrees of correlation in FTV between FLT and FDG-
PET images. FLT imaging may have a different meaning in determining tumor biology and prognosis.
Keywords: 18F-fluorothymidine, 18F-fluorodeoxyglucose, positron emission tomography/computed tomography, pancreatic 
cancer imaging, image processing, tumor proliferative activity, tumor glycolytic activity
33
Introduction
Pancreatic cancer (ductal adenocarcinoma) accounts 
for approximately 36,800 deaths per year in United States 
(1). The majority of patients present in the late stages of 
the disease with locally advanced or metastatic tumors, 
among which only 10 to 20% of patients are candidates 
for resection and hence have any potential for cure. The 
signs and symptoms of pancreatic cancer vary from vague, 
nonspecific abdominal complaints to severe jaundice and 
the diagnosis can often be difficult, especially in the early 
stages (2). Despite improvements in diagnostic technology 
and development of new systemic therapy agents, the 
prognosis of the disease has not shown much improvement. 
Surgical resection is the only potential curative treatment 
available for patients with pancreatic cancer (1). 
(18F)-fluorodeoxyglucose (FDG) positron emission 
tomography (PET)/computed tomography (CT) PET/CT 
has now become a standard imaging technique for most 
cancers and the majority of cancers exhibit increased glucose 
metabolism resulting in high concentration of 18F-FDG in 
lesions. FDG-PET can change the management of pancreatic 
cancer by revealing unsuspected metastases to liver, bone 
and lungs, thereby avoiding the morbidity and mortality of 
unnecessary surgical interventions (3). Proliferative activities of 
tumors are known to correlate with prognosis (4). Numerous 
markers have been described to predict the biological behavior 
of tumors and outcomes following surgical and medical 
treatment. Ki-67 is a nuclear antigen present only in the nuclei 
of proliferating cells and Ki-67 immunohistochemistry has 
been used to evaluate tumors’ proliferative activity (4,5,6). 
Clinical evaluation and quantification of proliferative activity 
and tumor invasiveness can be performed using 3’-deoxy-
3’-(18F)-fluorothymidine (18F-FLT) PET imaging (7,8,9,10,11). 
18F-FLT works as a terminator of the growing DNA chain 
(12). Actually little 18F-FLT is accumulated in DNA, it is rather 
retained intracellularly after phosphorylation by thymidine 
kinase 1. This is very much analogous to the imaging of the 
glucose pathway with 18F-FDG after trapping by hexokinase. 
Both compounds therefore reflect accumulation by transport 
and subsequent activation by the first step in the utilization 
pathways. However, 18F-FLT does not reflect the whole of 
DNA synthesis just as 18F-FDG does not reflect the whole of 
glucose use. 
In this study, we examined the imaging characteristics 
of pancreatic cancer patients to determine the correlation 
between the metabolic and proliferative activity of pancreatic 
cancer using FDG and FLT PET images, respectively. The 
parameters of interest were functional tumor volume (FTV), 
Total glycolytic index (TGI) and Total proliferative index (TPI). 
FTV, TGI and TPI were determined from both FDG and FLT 
PET images. These parameters measure the metabolic and 
proliferation activity of tumors using FDG and FLT PET/CT 
images, respectively, which have clinical value in the assessment 
of tumor biology, prognosis, response to treatment evaluation, 
and patient selection for therapeutic interventions (4). 
Materials and Methods
Inclusion Criteria
Patients with pancreatic and periampullary tumors were 
identified by pathological examination. Those who were 
potential candidates for the trial were further assessed 
for eligibility. Inclusion criteria were: clinically diagnosed 
pancreatic cancer (newly diagnosed as well as those under 
treatment), age ≥18, ability and willingness to give a 
written consent, life expectancy >3 months and Karnofsky 
performance status ≥70. Patients with age <18, inability or 
unwillingness to give a written consent, life expectancy <3 
months, Karnofsky performance status <70, pregnant or 
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Öz
Amaç: Bu faz I çalışma 3’-deoxy-3’-(18F)-fluorothymidine (18F-FLT) pozitron emisyon tomografisi (PET) görüntülemesinin 
pankreas kanseri hastalarındaki karakteristiklerini araştırmış ve sonuçlarını (18F)-fluorodeoxyglucose (18F-FDG) görüntülemesi 
ile karşılaştırmıştır. Bu çalışmadaki nihai amaç, pankreas kanserinin biyolojik özelliklerini tanımlayan ve pankreas kanseri 
hastaları arasında standart anatomik görüntüleme yöntemleri ile cerrahi tedavi imkanı olmadığı sonucuna varılan hastalarda 
cerrahi endikasyonlarının ve sınırlarının yeniden tanımlanmasını sağlayacak bir moleküler görüntüleme yöntemi geliştirmektir.
Yöntem: Yeni teşhis almış ve hiçbir tedavi görmemiş altı hasta bir hafta ara ile FLT ve FDG bilgisayarlı tomografi (BT) PET/
BT çalışmasına alındı. Tümör radyofarmasötik tutulumu tespit edilerek değişik yöntemlerle karsılaştırıldı. İstatistiki eşikleme (z 
skoru=2,5), sabit standart tutulum değeri standardized uptake value (SUV) olarak 1,4 ve 2,5, ve maksimum SUV değerinin 
%40’ı düzeyinde eşikleme yöntemleri denendi. FLT ve FDG ile fonksiyonel tümör hacmi hesaplamaları yapıldı ve ilişkileri lineer 
regresyon analizi ile araştırıldı.
Bulgular: FDG için 2,5 SUV ve FLT için 1,4 SUV değerleri kullanıldığında, FDG ve FLT fonksiyonel tümör hacimleri arasında 
bir korelasyon bulundu (r=0.698, p=ns). Her iki radyofarmasötik için 2,5 SUV değeri eşik alındığında ise fonksiyonel tümör 
hacimleri arasında daha iyi bir korelasyon saptandı (r=0.698, p=ns). Z skoru eşikleme yöntemiyle FLT ve FDG fonksiyonel tümör 
hacimleri arasında zayıf bir ilişki tespit edildi (r=0,698, p=ns). 
Sonuç: Değişik tümör segmentasyon yöntemleri FLT ve FDG fonksiyonel tümör hacimleri arasında değişik derecelerde 
korelasyon gösterdi. FLT görüntülemesi tümör biyolojisinin belirlenmesinde farklı bir anlamı ve prognostik değeri bulunabilir.
Anahtar kelimeler: 18F-fluorothymidine, 18F-fluorodeoxyglucose, pozitron emisyon tomografisi/bilgisayarlı tomografi, 
pankreas kanseri görüntülemesi, görüntü analizi, tümör proliferatif aktivitesi, tümör glikolitik aktivitesi
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nursing women (urine pregnancy test was performed prior 
to the investigational radiotracer injection) and individuals 
allergic to FLT were excluded. 
Patient Characteristics
Six patients fulfilling the inclusion criteria were enrolled 
in the study of which two were females and four were 
males (median age of 61.5 and range 56-71 years). The 
demographics of the patients with the estimated anatomic 
pancreatic volumes are presented in Table 1. The anatomic 
pancreatic volumes are estimated by outlining the pancreas 
on abdominal CT images by an expert radiologist.
Positron Emission Tomography/Computed 
Tomography Imaging
The study was performed under a Food and Drug 
Administration approved Investigational New Drug and 
after institutional review board review and approval. The 
3’-18F-fluoro-3’-deoxy-L-thymidine used in this trial was 
obtained from Cardinal Health 414, LLC. Administered 
activities both for 18F-FLT and 18F-FDG were 10±1 mCi with 
post injection imaging point of 60±15 minutes. Images 
were obtained with 16-slice Siemens PET/CT camera. The 
scanning parameters for the CT imaging were 140 kVp, 
80mA, 0.5s rotation time and 512×512-pixel matrix. CT 
image sizes range from 512x512x186 to 512x512x273. 
PET image sizes range from 168x168x186 to 168x168x273 
with voxel size of 4.0627x4.0627x4 mm3.
Methods for Finding Functional Tumor Volumes
As a first step, FLT PET images were manually co-
registered with FDG PET/CT images using AMIDE software, 
a free tool for viewing, analyzing and registering volumetric 
medical imaging data sets. Next, an experienced board 
certified radiologist used the region of interest (ROI) 
method to isolate the pancreas from CT images of the FDG 
PET/CT. After this point, MATLAB® (The MathWorks Inc.) 
was used to perform automatic tumor segmentation. The 
Binary masks from the ROIs of CT images were mapped to 
the co-registered FDG PET and FLT PET images to segment 
the pancreas. Third party interactive application software 
called ScanIPTM was used in 3D medical image analysis to 
estimate the volume of the segmented pancreas. Once the 
pancreas was segmented from the two images, different 
thresholding techniques were applied to find the FTVs. We 
have used statistical and SUV threshold techniques. 
 Our aim in this study was not to validate different tumor 
delineation methods, but rather to determine the FTV, TGI 
and TPI relationships due to the uptake of 18F-FDG and 
18F-FLT by using well practiced fixed threshold methods. 
Statistical Tumor Segmentation
The segmented pancreas was normalized by z score 
transformation using equation 1, where ‘x’ is the pixel 
intensity value, and ‘μ’ and ‘σ’ are the mean and standard 
deviation of the segmented pancreas images, respectively. 
The z score transformation procedure for normalizing 
data is a familiar statistical method in neuroimaging 
and psychological studies (3). This method converts the 
original pixel intensity image to a probability map that 
represents deviations from the normal using voxel-by-voxel 
comparison, which facilitates image interpretation. 
The z score, which transforms the image into a 
statistical parametric map, was calculated for each 
pixel. Threshold of z≥2.5 was then applied which only 
highlights those pixels which can confidently be labelled 
as active, i.e. those areas which deviate significantly 
from the normal (13). Using this technique considers 
the low tumor to background ratio by comparing each 
pixel to the surrounding pixels through deviation from 
the mean.
Standardized Uptake Value (SUV) Based Tumor 
Segmentation
SUV provides biological and functional activity of a tumor 
(14). Quantification of FLT with SUV provides information 
about cells undergoing active proliferation while SUV of 
FDG provides information on increased glucose metabolism. 
SUVs were calculated with mathematical expression shown 
in equation 2. 
Different SUV thresholds were used to investigate tumor 
localization; SUV of 1.4, 2.5, 40% SUVmax and SUVmean. 
SUVmax and SUVmean refer to the maximum and mean 
SUV values from each individual patient’s PET images. 
One of the methods was using 40% of the maximum SUV 
uptake for each patient to segment tumor. Each patient 
has different maximum SUV uptakes for the radiotracer 
type, thus the amount of threshold varies accordingly. 
From the maximum SUVs, 40% of this value (40% SUVmax) 
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Table 1. Patient characteristics
Patient 
no
Age 
(years)
Gender Volume of 
Pancreas (ml)
SUVmax
18F-FDG 18F-FLT
1 71 M 206 33.21 16.52
2 67 F 143 5.85 2.60
3 57 M 248 5.45 12.25
4 56 M 120 5.30 9.17
5 62 M 107 1.32 3.12
6 61 F 96.3 3.46 5.12
M: Male, F: Female, 18F-FDG: 2-deoxy-2-(18F)-fluoro-D-glucose, 18F-FLT: 3’-18F-fluoro-
3’-deoxy-L-thymidine, FDG: Fluorodeoxyglucose, FLT: Fluorothymidine
was applied as a threshold to segment tumors. The same 
concept was used when the mean SUV (SUVmean) uptake 
for tumor segmentation was applied. Table 1 shows the 
maximum SUVs for each patient. 
Functional Tumor Volume Measurement
The voxels, which exceed the applied threshold value, 
were counted to find the FTV using equation 3 where AV is 
the active voxel that remained after applying the threshold. 
Volume of a voxel was 4.0627x4.0627x4 mm3. The FTVs 
for 18F-FLT and 18F-FDG were then assessed using linear 
regression analysis.
Total Glycolytic and Total Proliferative Index 
Measurements 
The TGI/TPI is the product of functional volume and 
tumor SUVmax. The FTV were multiplied with the respective 
SUVmax of the patient. 
Results
Results of FTVs (ml) using the different tumor segmentation 
methods on 18F-FDG and 18F-FLT PET images are presented 
in Table 2 (A) and (B) respectively. Linear regressions were 
performed between estimated FTV from 18F-FDG and 18F-FLT 
PET for the five different thresholding techniques shown in 
Figure 1. Correlation coefficients (r), t and p values of the 
linear regression were reported. Analyses were performed 
two-sided at a 5% level of significance. Figure 2 shows the 
3D rendered images of the pancreas and segmented tumors 
using the five different threshold techniques for patient 3. 
FDG and FLT PET images with average maximum 
SUV uptake of 9.1 (median 5.38, range 1.32-33.21) and 
8.1 (median 7.15, range 2.6-16.52), respectively, were 
analyzed. Results showed a correlation in FTV due to 
metabolic and proliferation activity. Using a threshold of 
SUV 2.5 for FDG and 1.4 for FLT, a correlation coefficient 
(r) of 0.9606 (t value=7.16, p value <0.05) was found. A 
slightly better correlation was found with SUV of 2.5 for 
both tracers with of r=0.973 (t value=8.46, p value <0.05). 
The p values (5% significance level) from the two SUV 
methods strongly support that there is a correlation in FTV 
from 18F-FDG and 18F-FLT PET scans. 
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Table 2B. Estimated pancreas tumor volumes using (B) 18F-FLT PET/CT Imaging
Patient no z score(z=2.5)
SUV based 
(FDG=2.5, FLT=1.4)
SUV based 
(FDG=2.5, FLT 2.5) 40% SUVmax SUVmean
1 20.53 146.04 67.21 9.44 63.78
2 27.60 18.68 0.20 33.74 60.87
3 25.42 95.14 62.00 31.69 57.90
4 8.06 38.43 15.25 9.71 17.69
5 12.54 15.12 2.05 20.40 25.35
6 12.74 34.60 12.94 19.41 33.94
Average 17.82±7.18 58.00±47.34 26.61±27.44 20.73±9.49 43.26±18.29
18F-FLT: 3’-18F-fluoro-3’-deoxy-L-thymidine, PET/CT: Positron emission tomography/computed tomography, SUV: Standardized uptake value, FDG: Fluorodeoxyglucose, 
FLT: Fluorothymidine, Averages values are expressed as mean ± SD
Table 2A. Estimated pancreas tumor volumes using (A) 18F-FDG PET/CT Imaging
Patient no z score(z=2.5)
SUV based 
(FDG=2.5, FLT=1.4)
SUV based 
(FDG=2.5, FLT 2.5) 40% SUVmax SUVmean
1 30.90 126.83 126.83 8.06 59.82
2 29.91 11.36 11.36 13.60 57.57
3 76.39 104.65 104.65 142.28 117.12
4 11.16 5.74 5.74 10.70 52.49
5 20.34 0.00 0.00 33.01 30.12
6 20.86 2.25 2.25 32.42 42.58
Average 31.59±21.09 41.81±52.79 41.81±52.79 40.01±46.80 59.95±27.45
18F-FDG: 2-deoxy-2-(18F)-fluoro-D-glucose, PET/CT: Positron emission tomography/computed tomography, SUV: Standardized uptake value, 
FDG: Fluorodeoxyglucose, FLT: Fluorothymidine, Averages values are expressed as mean ± SD
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Strong correlation between TPI and TGI was found 
using 40% of SUVmax, r of 0.9977 (t value=29.37, p<0.05). 
The 2nd best correlation between TPI and TGI was observed 
when threshold of SUV 1.4 for FLT and 2.5 for FDG used 
with r=0.9427(t value=5.65, p value <0.05).
The z score threshold (z=2.5) method showed 
a moderate correlation between FTVs (r=0.698, 
t value=1.95, p value=ns), and TGI and TPI (r=0.89, 
t value=3.9, p value <0.05) between the two images. 
The p values support the null hypothesis that there is no 
correlation between the FTVs of FDG and FLT PET images 
with z score method. 
Discussion
There is no universally validated technique for tumor 
delineation, and manual segmentation is biased by the 
experience of the nuclear physician and the contouring 
protocol used. Thureau et al. (15) has suggested using a 
fixed threshold of SUV 1.4 for 18F-FLT uptake due to the low 
tumor-to-background ratio in PET images of lung cancer. 
In addition, it was also demonstrated that using SUV of 
1.4 gives a similar result as the method used by physicians 
to delineate tumors. It is also explained in the literature 
that the difference in tumor volumes using different SUV 
thresholds to segment 18F-FDG uptake was insignificant. 
Han et al. (16) also concluded that SUV cutoff of 1.4 for 
18F-FLT PET/CT and SUV of 2.5 for 18F-FDG PET/CT provided 
the best estimate of gross tumor volume. Hellwig et al. 
(17) demonstrated that SUV of 2.5 thresholds for 18F-FDG 
gives a high overall accuracy for clinical images. In our 
study, SUV cutoff values that showed to be reproducible 
were used for tumor segmentation. The resulting volumes 
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Figure 1. Functional tumor volume relationships using (A) z score thresholding, (B) SUV cutoffs of 2.5 for FDG and 1.4 for FLT (C) SUV cutoffs of 2.5 for 
both FDG&FLT (D) 40% of SUVmax thresholding (E) SUVmean threshold
FDG:Fluorodeoxyglucose, FLT: Fluorothymidine
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from 18F-FDG and 18F-FLT PET images were compared for 
correlation. 
In our study, the FLT PET images demonstrated 
physiologic uptake in the liver and bone marrow. The activity 
in the normal pancreatic tissue was at the background 
level. FLT uptake in the tumors was at variable intensity 
and did not encompass the entirety of the FDG-positive 
regions in the tumor’s topography. Determining FTV from 
FLT PET images is challenged by partial volume effect (in 
small tumors), and is subject to errors from manual tumor 
segmentation that might result in underestimation. These 
drawbacks have been explained as a reason for negative 
results in FLT PET scans (18). The FTV from FDG PET images 
could also be potentially challenged by the enhancement 
of FDG activity from a peritumoral inflammatory response. 
Thus, a technique that is ideal for FDG images might not 
necessarily be applicable to FLT images. To address these 
technical difficulties, we used semiautomatic segmentation 
methods. The primary aim of this study was to assess and 
compare the topography and size of FTV from proliferation 
(FLT PET) and metabolic (FDG PET) images. 
In this study, the pancreas was first segmented from 
18F-FDG CT scans by an experienced radiologist. The 
segmented pancreas was then mapped to co-registered 
18F-FDG and 18F-FLT PET images. Different thresholding 
techniques were applied to automatically segment tumors 
from the PET scans. 
We used two major methods; statistical and SUV methods. 
To our knowledge, this study is the first to use a statistical 
(z score) and fixed SUV thresholds on FLT and FDG PET/CT 
images of pancreatic cancer in tumor segmentation. The use 
of z score threshold considers all pixels inside the pancreas 
and delineates only those pixels that deviate considerably 
from the mean activity inside the pancreas. In the case of FLT 
PET images that have very low contrast, this method provides 
an excellent way to differentiate between background and 
tumor pixel intensities. Z scores on FLT images take into 
consideration the overall organ uptake since not every organ 
has similar cell proliferation rates. This method might not 
provide an alternate choice for FDG PET images where tumor 
to background uptake is well segregated. 
The SUV cutoffs (2.5, 1.4, 40% SUVmax and SUVmean) 
presented here to segment tumor volumes have been 
tested to be reproducible in tumor volume delineation 
(15,17,19). We have found different FTVs from FDG and 
FLT PET images, which might result in different treatment 
planning and different dose delivery if either of the two 
tracers is used for diagnostics workup. This might imply 
that giving a treatment solely based on FLT or FDG uptake 
might be misleading suggesting that incorporating the two 
images can be beneficial in treatment planning.
There is a satisfactory FTV correspondence between FDG 
and FLT PET when SUV cutoffs of 2.5 and 1.4, respectively, 
are used for tumor segmentation. The correlation between 
TGI and TPI is seen to be high when a threshold of 40% 
of SUVmax is used but this method also gave the highest 
probability of false prediction. 
 Though the volumes delineated as a tumor from the 
two images do not always occur in the same place of the 
pancreas, our study showed that FTVs from 18F-FDG and 
18F-FLT PET images do have correlation. In most patients, 
it was observed that tumors segmented from FLT PET 
images occur at the head of the pancreas (Figure 2). 
Thureau et al. (15) postulated that proliferative volume 
should not be greater than metabolic volume. In our study, 
the z score method yielded higher tumor volumes from 
18F-FDG than 18F-FLT PET images in all patients unlike the 
SUV methods where this result was variable from patient 
to patient. 
In conclusion, the FTVs correlation seen between 
FDG and FLT PET scans depends on the type of tumor 
segmentation technique used. SUV based thresholds 
showed correlations in the FTVs but z score method showed 
no correlations of FTVs between FDG and FLT PET scans. 
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Figure 2. 3D rendered volume of pancreas (red) and tumor volume 
delineated based on the uptake of only FDG (yellow) (left), and FDG and 
FLT (pink) superimposed (right) for patient 3 using (a)-(b) z score, (c)-(d) 
SUV of 2.5 (FDG) & 1.4 (FLT), (e)-(f) SUV of 2.5 for both tracers, (f)-(g) 40% 
SUVmax and (h)-(i) SUVmean thresholding
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Conclusions
Different tumor segmentation techniques yielded varying 
degree of correlation in functional tumor values between 
FLT and FDG PET images. The statistical threshold technique 
showed higher tumor volumes from FDG images than from 
FLT PET images in all patients. Due to the limited number of 
patients and the lack of a gold standard, further investigation 
is required to fully appreciate correlations in tumor topography 
and size between 18F-FDG PET and 18F-FLT PET images.
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